2019•Document Server@UHasselt (UHasselt)Requires access
Comparative effectiveness of natalizumab and fingolimod in different subgroups of patients with relapsing-remitting multiple sclerosis
Sifat Sharmin, Mathilde Lefort, Jens Rikardt Andersen, Dana Horáková, Eva Havrdová, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Serkan Özakbaş, Helmut Butzkueven, Francesco Patti, Marco Onofrj, Alessandra Lugaresi, Murat Terzi, Pierre Grammond, F. Grand’Maison, Bassem Yamout, Alexandre Prat, Marc Girard, Pierre Duquette, Cavit Boz, María Trojano, Pamela McCombe, Mark Slee, Jeannette Lechner‐Scott, Recai Türkoğlu, Patrizia Sola, Diana Ferraro, Franco Granella, Vahid Shaygannejad, Julie Prévost, Olga Skibina, Claudio Solaro, Rana Karabudak, B. Van Wijmeersch, Tünde Csépány, Daniele Spitaleri, Steve Vucic, Emmanuelle Leray, Per Soelberg Sørensen, Finn Sellebjerg, Melinda Magyari, Sandra Vukusic, Tomáš Kalinčík
Open publisher page 0 citations
Abstract
Pierre Duquette served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme.